Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Can correcting the ΔF508-CFTR proteostasis-defect rescue CF lung disease?

Valle CW, Vij N.

Curr Mol Med. 2012 Aug;12(7):860-71. Review.

PMID:
22697346
2.

CFTR: folding, misfolding and correcting the ΔF508 conformational defect.

Lukacs GL, Verkman AS.

Trends Mol Med. 2012 Feb;18(2):81-91. doi: 10.1016/j.molmed.2011.10.003. Epub 2011 Dec 3. Review.

3.
4.

Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.

Roomans GM.

Am J Respir Med. 2003;2(5):413-31. Review.

PMID:
14719993
5.
6.

Pharmacological treatment of the ion transport defect in cystic fibrosis.

Roomans GM.

Expert Opin Investig Drugs. 2001 Jan;10(1):1-19. Review.

PMID:
11116277
7.

Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.

Amaral MD.

Curr Drug Targets. 2011 May;12(5):683-93. Review.

PMID:
21039334
8.

Novel pharmacological strategies to treat cystic fibrosis.

Hanrahan JW, Sampson HM, Thomas DY.

Trends Pharmacol Sci. 2013 Feb;34(2):119-25. doi: 10.1016/j.tips.2012.11.006. Review.

PMID:
23380248
9.

Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery.

Eidelman O, Zhang J, Srivastava M, Pollard HB.

Am J Pharmacogenomics. 2001;1(3):223-38. Review.

PMID:
12083969
10.

Therapeutic strategies to correct proteostasis-imbalance in chronic obstructive lung diseases.

Bodas M, Tran I, Vij N.

Curr Mol Med. 2012 Aug;12(7):807-14. Review.

PMID:
22697347
11.

Macromolecular interactions and ion transport in cystic fibrosis.

Guggino WB, Banks-Schlegel SP.

Am J Respir Crit Care Med. 2004 Oct 1;170(7):815-20. Review.

PMID:
15447951
12.

[Early bronchial inflammation in cystic fibrosis].

Puchelle E.

J Soc Biol. 2002;196(1):29-35. Review. French.

PMID:
12134630
13.

[Physiopathology of cystic fibrosis lung disease].

Chinet T.

Rev Mal Respir. 1999 Jun;16(3):339-45. Review. French.

PMID:
10472642
14.
15.

How do cystic fibrosis transmembrane conductance regulator mutations produce lung disease?

Pilewski JM, Frizzell RA.

Curr Opin Pulm Med. 1995 Nov;1(6):435-43. Review.

PMID:
9363079
16.

Cytoskeleton and CFTR.

Edelman A.

Int J Biochem Cell Biol. 2014 Jul;52:68-72. doi: 10.1016/j.biocel.2014.03.018. Epub 2014 Mar 28. Review.

PMID:
24685681
17.

Repairing the basic defect in cystic fibrosis - one approach is not enough.

Farinha CM, Matos P.

FEBS J. 2016 Jan;283(2):246-64. doi: 10.1111/febs.13531. Epub 2015 Oct 18. Review.

18.

Novel Approaches for Potential Therapy of Cystic Fibrosis.

Sawczak V, Getsy P, Zaidi A, Sun F, Zaman K, Gaston B.

Curr Drug Targets. 2015;16(9):923-36. Review.

PMID:
25557257
19.

Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis.

Esposito S, Tosco A, Villella VR, Raia V, Kroemer G, Maiuri L.

Mol Cell Pediatr. 2016 Dec;3(1):13. doi: 10.1186/s40348-016-0040-z. Epub 2016 Mar 14. Review.

20.

Supplemental Content

Support Center